Websites
Xinxue Liu
Associate Professor of Medical Statistics and Epidemiology
I completed a Preventive Medicine Degree at Peking University. After that, I was trained in Epidemiology and Biostatistics at Peking University and University of Cambridge and obtained my PhD and MPhil degrees.
I joined the Oxford Vaccine Group Department of Paediatrics in 2017 after receiving more than 4 years of training as a Research Fellow (Clinical Trial Statistician) at the Imperial Clinical Trial Unit.
My experiences in trials cover a broad range of therapeutic areas, including cancer, surgery, nutrition and vaccination and ranging from early phase to late phase. My research interest is mainly in developing efficient trial designs and practical implementation of such designs in clinical trials, for example, model based adaptive designs in early phase dose-finding trials evaluating safety and efficacy. I am also interested in applying biomarkers in late phase trial design and benefit and risk assessment.
Recent publications
-
The validity of test-negative design for assessment of typhoid conjugate vaccine protection: comparison of estimates by different study designs using data from a cluster-randomised controlled trial.
Feng S. et al, (2025), Lancet Glob Health
-
The effect of pertussis vaccination in pregnancy on the immunogenicity of acellular or whole-cell pertussis vaccination in Gambian infants (GaPS): a single-centre, randomised, controlled, double-blind, phase 4 trial.
Saso A. et al, (2025), Lancet Infect Dis
-
Evaluation of naturally occurring IgG anti-Vi antibody titers as predictors and correlates of typhoid fever in Dhaka, Bangladesh.
Khanam F. et al, (2025), BMC Infect Dis, 25
-
Past, present, and future of Phase 3 vaccine trial design: rethinking statistics for the 21st century.
Janani L. et al, (2025), Clin Exp Immunol, 219
-
Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST).
Marchese AM. et al, (2025), Vaccine, 44